Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Castle Biosciences Inc. (CSTL) Tops Q4 EPS by 6c; Offers FY23 Revenue Guidance
February 28, 2023 4:33 PM ESTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q4 EPS of ($0.78), $0.06 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $38.3 million versus the consensus estimate of $37.15 million.
GUIDANCE:
Castle Biosciences Inc. sees FY2023 revenue of $170-180 million, versus the... More
